Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04450173 · ClinicalTrials.gov registry record · Phase 2

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

A Phase 2 study of Grade 3a Follicular Lymphoma and Grade 1 Follicular Lymphoma, sponsored by Joseph Tuscano.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
4
Study locations

NCT04450173 is a Phase 2 study of Grade 3a Follicular Lymphoma and Grade 1 Follicular Lymphoma that is actively recruiting participants, run by Joseph Tuscano. The registered enrollment target is 40 participants, roughly in line with the 39-participant average among 10 other Grade 3a Follicular Lymphoma trials with a reported enrollment target. The trial reports 4 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04450173, a Phase 2 study of Grade 3a Follicular Lymphoma and Grade 1 Follicular Lymphoma, is actively recruiting participants, sponsored by Joseph Tuscano.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
4
Study locations

Study Summary

This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and venetoclax together may work better in treating follicular lymphoma compared to each drug alone.

Conditions Studied

Grade 3a Follicular Lymphoma Grade 1 Follicular Lymphoma Grade 2 Follicular Lymphoma Ann Arbor Stage II Follicular Lymphoma Ann Arbor Stage III Follicular Lymphoma Ann Arbor Stage IV Follicular Lymphoma

Interventions

  • DRUG Venetoclax
  • BIOLOGICAL Obinutuzumab
  • DRUG Ibrutinib

Study Locations (4)

California

  • University of California, San Francisco (UCSF) Fresno - Fresno
  • University of California, Los Angeles - Los Angeles
  • University of California Davis Comprehensive Cancer Center - Sacramento
  • University of California, San Diego - San Diego

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-02-24
Est. Completion 2026-04
Phase Phase 2

Sponsor

Joseph Tuscano

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04450173

The ClinicalTrials.gov registry entry for NCT04450173 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 39-participant average among 10 other Grade 3a Follicular Lymphoma trials with a reported enrollment target. The listed sponsor is Joseph Tuscano, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Grade 3a Follicular Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT04450173 reports 4 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04450173 about?

NCT04450173 is a clinical study titled "Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma". This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and s...

What is the current status of trial NCT04450173?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-02-24. Estimated completion is 2026-04.

What conditions does trial NCT04450173 study?

This clinical trial studies the following conditions: Grade 3a Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma.

What interventions are being tested in trial NCT04450173?

The interventions under investigation include: Venetoclax (DRUG), Obinutuzumab (BIOLOGICAL), Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT04450173?

This trial is sponsored by Joseph Tuscano, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04450173 being conducted?

This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Grade 3a Follicular Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Grade 3a Follicular Lymphoma

All registered trials for this condition

Grade 1 Follicular Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.